Natural killer cell immunotherapy for cancer: a new hope.
Recently there has been a substantial gain in our understanding of the role NK-cells play in mediating innate host immune responses. Although NK cells have long been known to mediate antigen independent tumor cytotoxicity, the therapeutic potential of NK cell-based immunotherapy has yet to be realized. Manipulating the balance between inhibitory and activating NK receptor signals, sensitization of tumor target cells to NK cell-mediated apoptosis, and recent discoveries in NK-cell receptor biology have fueled translational research that has led to clinical trials investigating a number of novel methods to potentiate NK cytotoxicity against human malignancies.
Srivastava
S
S
National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA.
Lundqvist
A
A
Childs
R W
RW
D000818:Animals; D000920:Antibody-Dependent Cell Cytotoxicity / Q000276:immunology; D051017:Apoptosis Regulatory Proteins / Q000276:immunology / Q000378:metabolism; D003131:Combined Modality Therapy; D003602:Cytotoxicity, Immunologic / Q000235:genetics / Q000276:immunology; D025461:Feedback, Physiological / Q000235:genetics / Q000276:immunology; D020350:Graft vs Tumor Effect / Q000276:immunology; D006648:Histocompatibility; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000379:methods / Q000639:trends*; D007694:Killer Cells, Natural / Q000276:immunology* / Q000378:metabolism; D009369:Neoplasms / Q000276:immunology* / Q000473:pathology / Q000628:therapy*; D054340:Receptors, KIR / Q000235:genetics / Q000276:immunology / Q000378:metabolism*; D011993:Recombinant Fusion Proteins / Q000235:genetics / Q000276:immunology / Q000378:metabolism*; D014162:Transfection
D051017:Apoptosis Regulatory Proteins; D054340:Receptors, KIR; D011993:Recombinant Fusion Proteins